Not a Lexis Advance subscriber? Try it out for free.


Mealey's IP/Tech - High Court Won't Hear Dispute Over Patented Schizophrenia Drug

WASHINGTON, D.C. - In its Jan. 13 order list, the U.S. Supreme Court rejected a petition for certiorari that poses the question of whether method-of-treatment patent claims automatically satisfy Section 101 of the Patent Act, even if they consist only of application of natural law using routine steps (Hikma Pharmaceuticals USA Inc., et al. v. Vanda Pharmaceuticals USA Inc., No. 18-817, U.S. Sup.).
Find full version on lexis Advance®